Therapy Areas: Cardiovascular
Ionis partner Novartis reports pelacarsen Phase 3 trial misses primary endpoint
7 September 2026 - RNA therapy company Ionis Pharmaceuticals Inc (Nasdaq: IONS) disclosed on Monday that its partner Novartis reported topline results from the Phase 3 Lp(a)HORIZON study and said pela...
Thryv Therapeutics licenses new class of SGK1 inhibitors, expanding into neurodegenerative disease
4 September 2026 - Thryv Therapeutics Inc, a clinical-stage biopharmaceutical company advancing selective SGK1 inhibitors, announced on Thursday that it has entered into an exclusive, worldwide, royal...
Lilly to acquire Merida Biosciences in USD2.875bn deal
31 August 2026 - US pharmaceutical company Eli Lilly and Company (NYSE: LLY) on Monday announced that it has agreed to acquire Merida Biosciences, Inc., a biotechnology business developing precision b...
GE HealthCare expands Vivid cardiovascular ultrasound portfolio with three new systems
28 August 2026 - Medical technology company GE HealthCare (Nasdaq:GEHC) on Friday unveiled three additions to its Vivid cardiovascular ultrasound portfolio: Vivid Explorer, Vivid Advanced and Vivid Fo...
Daiichi Sankyo data highlight real-world impact of bempedoic acid on cardiovascular risk
28 August 2026 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) said on Friday that new analyses from the multinational MILOS study demonstrate the real-world impact of bempedoic acid, u...
Revier Therapeutics closes EUR6m seed financing and launches operations
26 August 2026 - German pharmaceutical company Revier Therapeutics announced on Tuesday the closing of a EUR6m seed financing and the launch of its operations.The company says that it has established ...